BIO Share Price

Open 27.65 Change Price %
High 28.00 1 Day -0.10 -0.36
Low 27.53 1 Week -0.41 -1.45
Close 27.90 1 Month -0.10 -0.36
Volume 360 1 Year 10.90 64.12
52 Week High 29.09
52 Week Low 15.70
BIO Important Levels
Resistance 2 28.34
Resistance 1 28.16
Pivot 27.81
Support 1 27.64
Support 2 27.46
ETR Germany Most Active Stocks
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
DTE 15.46 0.78%
CBK 11.23 0.18%
CBK 11.23 0.18%
EOAN 9.31 1.20%
EOAN 9.31 1.20%
DBK 13.90 -0.29%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
MGN 2.96 21.31%
MGN 2.96 21.31%
5M71 39.00 13.70%
R3Q 0.11 10.00%
AB1 0.43 7.50%
TPE 5.09 7.16%
USE 0.15 7.14%
BEO 3.38 6.96%
F3A 43.28 6.63%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
RLI 21.30 -51.16%
RLI 21.30 -51.16%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
MXW 4.15 -23.15%
ANO 0.08 -11.11%
ANO 0.08 -11.11%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 4
As on 22nd Sep 2017 BIO Share Price closed @ 27.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 22.90 & Buy for SHORT-TERM with Stoploss of 27.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for September
1st Target up-side 29.51
2nd Target up-side 30.22
3rd Target up-side 30.93
1st Target down-side 27.49
2nd Target down-side 26.78
3rd Target down-side 26.07
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.